Title
Category
Credits
Event date
Cost
Understanding OCT-A: Advanced retinal imaging for diabetic eye care
  • Disease management
  • Vision
  • 1.00 Attendance - General Attendance
  • 1.00 COPE - Optometrists
$0.00
Activity descriptionOptical coherence tomography angiography (OCT-A) is a noninvasive imaging test and allows clinicians to detect diseases of the retina that affect the ocular blood vessels at early stages. This activity is designed to enhance clinicians’ understanding and application of OCT-A in practice. Participants will explore the evolution of OCT-A technology, compare it with traditional imaging modalities and examine its clinical relevance.
Advancing Neonatal Care: Implementing the Eat, Sleep, Console (ESC) Method for Neonatal Abstinence Syndrome (Podcast)
  • Women's health
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
In this podcast episode, Advancing Neonatal Care: Implementing the Eat, Sleep, Console (ESC) Method for Neonatal Abstinence Syndrome, Dr. Monica Hajdena-Dawson and Tara Sundem dive into the Eat, Sleep, Console method for managing Neonatal Abstinence Syndrome—featuring powerful stories from families and caregivers who’ve experienced it firsthand. Tune in to gain a deeper, human-centered understanding of ESC and how it’s transforming neonatal care.
Advancing Neonatal Care: Implementing the Eat, Sleep, Console (ESC) Method for Neonatal Abstinence Syndrome
  • Disease management
  • Women's health
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
Activity descriptionNeonatal Abstinence Syndrome (NAS) continues to pose significant clinical challenges, with rising incidence rates and prolonged hospital stays. The Eat, Sleep, Console (ESC) method offers a functional, family-centered approach that has demonstrated improved outcomes, including reduced length of stay and decreased medication use.
Heart Failure at the Crossroads: Early Recognition and Proactive Management
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Heart failure remains a leading cause of hospitalization and mortality. This session focuses on recognizing early signs, diagnostic tools, and evidence-based strategies to optimize care, improve patient quality of life, and reduce readmissions.
Health Equity Foundations: Ensuring No One Is Left Behind
  • Health equity
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 CDR - Dietitians
  • 0.75 COPE - Optometrists
$0.00
This on-demand activity introduces health equity concepts, explores root causes of disparities, and provides frameworks for addressing social drivers of health and health-related social needs. By the end, learners will gain practical tools to identify inequities and integrate equity principles into daily work to improve outcomes and organizational value.
GLP-1 Agonists in Practice: A New Era in Obesity and Diabetes Management
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 ASWB - Social Workers
$0.00
GLP-1 receptor agonists have reshaped the landscape of obesity and type 2 diabetes management, offering benefits beyond glycemic control. This session explores their mechanisms, clinical applications, and emerging evidence on their implications for broader metabolic care and in the treatment of obesity-related conditions such as obstructive sleep apnea.
Gene Therapy in the Genomic Era: Promise, Progress and Patient Impact
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
Gene therapy technologies are revolutionizing treatment for genetic diseases. This session explores the science, clinical applications, and patient perspectives, with a focus on sickle cell disease and emerging technologies like CRISPR.
COPD in 2025: Early Detection, Diagnostic Precision, and Emerging Therapies
  • Disease management
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This session explores the latest updates in the diagnosis and management of chronic obstructive pulmonary disease (COPD) as outlined in the 2025 GOLD Report. Early case finding, refined spirometry protocols and novel therapeutic options are discussed, along with the importance of pre-bronchodilator spirometry, strategies for early detection in at-risk populations, and the integration of new treatments into updated treatment algorithms.
Facing Dementia: Early Diagnosis, Communication and Compassionate Care
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 ASWB - Social Workers
$0.00
Dementia care poses growing challenges in health care, requiring early recognition, accurate diagnosis, and compassionate, evidence-based care. This activity clarifies distinctions between dementia and mild cognitive impairment, reviews common subtypes, and highlights core strategies for improving care delivery and enhancing support for patients and caregivers.
Fatty Liver Disease: The Silent Epidemic
  • Disease management
  • Transplantation
  • 1.25 ACPE - Pharmacists
  • 1.25 ACPE - Pharmacy Technicians
  • 1.25 AMA - Physicians
  • 1.25 ANCC - Nurses
  • 1.25 APA - Psychologists
  • 1.25 Attendance - General Attendance
  • 1.25 ASWB - Social Workers
$0.00
This presentation reviews the latest evidence-based strategies for identifying, diagnosing and managing non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). The progressive form of this disease, non-alcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in the United States. Learn about current guidelines, risk-stratification tools, and emerging therapies, and gain insights to improve early detection and optimize patient outcomes.

Pages